UNSPSC 51182024: Danazol

This classification denotes a therapeutic androgen, gonadotropin releasing hormone inhibitor, and anabolic steroid with the molecular formula C22H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N29QWW3BUO, chemically known as win 17,757 but generally known as danazol, which bears US NIH Compound Identifier 2949. European Medicines Agency schedules Danazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06897MIG. The term DANAZOL is an International Non-Proprietary Name.

UNSPSC 51182024 Danazol is a Commodity code that covers the procurement of danazol, a synthetic steroid medication used to treat endometriosis, fibrocystic breast disease, and hereditary angioedema in state and local healthcare and correctional settings. State and local governments purchase danazol primarily through their pharmacy benefit management programs, correctional healthcare systems, and public health departments to support inpatient and outpatient treatment protocols. Issuing bodies include state departments of corrections, state health departments, county jail systems, and public hospitals or health authorities that maintain formularies and medication inventories for patient care.

The source provided contains no records of recent state and local contract opportunities solicited under this code, preventing characterization of current geographic activity, issuing-body concentration, or representative recent solicitations.